PIPERTON, TN: In a groundbreaking advancement for cardiothoracic surgery, CircumFix Solutions, Inc. has been officially granted U.S. Patent No. 12,616,509 for its revolutionary “Sternum fixation device and method.” This newly issued patent introduces an innovative, polymer-based implantable matrix designed to stabilize and optimize the healing of a surgically severed or fractured sternum, establishing a new paradigm for post-operative patient recovery and surgical closure safety.

In recognition of its significant clinical utility and engineering excellence, this proprietary technology has been awarded the prestigious title of Tennessee State Patent of the Month for June 2026. This honor celebrates the Piperton-based medical device developer for driving scientific boundaries and strengthening the state of Tennessee as a prominent national ecosystem for advanced orthopedic and biomedical technology innovation.

Unmatched Innovation in Sternal Closure Design

Traditional sternal closure techniques have long relied on rigid stainless steel cerclage wires or heavy metal plating systems. While these conventional methods are widely utilized, they carry post-operative complication rates as high as 8 percent, often resulting in deep wound infections, hardware failure, or bone cutting due to the thin cortical shell of the human sternum. CircumFix Solutions effectively resolves these critical clinical challenges by introducing a state-of-the-art polymer assembly.

The patented device consists of a slender chest plate coupled with high-strength locking fasteners designed to securely encircle the bone segments. Fabricated from an implant-grade, biocompatible, and hydrophobic high-performance polymer known as PEEK (polyetheretherketone), the assembly conforms dynamically to the patient’s unique thoracic anatomy. This unibody construction achieves exceptional three-dimensional stability and promotes optimal load sharing between the bone and the device. By dispersing physiological forces uniformly across the anterior table of the sternum, it eliminates the localized stress concentrations that cause metal wires to slice through fragile bone tissue, a phenomenon often called the cheese-grater effect. Furthermore, the hydrophobic properties of PEEK minimize bacterial adherence, substantially reducing infection risks compared to metal alternatives.

Beyond its structural advantages, this innovation offers unprecedented diagnostic transparency and emergency accessibility. Because PEEK is entirely radiolucent, the implant does not obstruct post-operative X-rays or CT scans, allowing clinicians to monitor bone fusion with absolute clarity. Most critically, if a patient experiences an acute, life-threatening cardiac event requiring immediate chest re-entry, the device can be rapidly unlocked and reopened by surgical teams without specialized, proprietary instruments. It can then be securely re-locked once the emergency intervention is complete, preserving vital time when every second counts.

Why It Earned Tennessee’s June 2026 Patent of the Month Distinction

Securing the Patent of the Month distinction for June 2026 highlights the immense healthcare and economic value this technology introduces to the state. Headquartered in Piperton, Tennessee, CircumFix Solutions exemplifies the high-caliber scientific research and technical enterprise thriving within the region’s biotech corridors. With hundreds of thousands of median sternotomies performed annually in the United States, the commercial scalability and clinical impact of a safer, more reproducible closure system are profound. By decreasing costly, painful post-operative complications and reducing intensive care re-admissions, this homegrown Tennessee innovation provides substantial economic relief to the healthcare system while positioning the state as a leader in global medical pioneering.

U.S. R&D Tax Credit Eligibility for Practical Applications

The practical applications involved in developing and refining this patented technology represent classic qualifying activities for the United States Research and Development (R&D) Tax Credit under IRC Section 41. To successfully claim this incentive, a company must document how its iterative engineering cycles satisfied the statutory Four-Part Test. Overcoming the technical uncertainties of transitioning from traditional rigid metal hardware to an anatomically conforming, load-sharing polymer matrix required an extensive process of experimentation. Engineers had to design, prototype, and mechanically test various PEEK configurations and locking band geometries to ensure they could withstand cyclic physiological forces, such as respiration and heavy coughing. Because these activities directly relied on the principles of materials science, mechanical engineering, and structural biology to achieve a higher-performing medical product, the associated employee wages, qualified supply expenses, and independent laboratory testing costs are fully eligible for valuable tax credits.